A Phase 3 interventional study of DTX301 and Placebo in OTC Deficiency, sponsored by Ultragenyx Pharmaceutical Inc. Active, not recruiting at 16 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Ultragenyx Pharmaceutical Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States — 6 open to participants now, 11 under way, 2 of them phase 3. Ornithine Carbamoyltransferase Deficiency Disease · United States.
Among the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 3, reaches primary completion later than 5 of the 10 other live ones, and was the 25th registered.
59 studies on the registry are indexed under Ornithine Carbamoyltransferase Deficiency Disease; 13 are open to participants now.
Browse Ornithine Carbamoyltransferase Deficiency Disease studies →6 of the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States are open now. Recruiting first, the newest first:
iECURE, Inc. · Sites in United States, France, United Kingdom
Ages 7 mo–15 mo
Arcturus Therapeutics, Inc. · Sites in United States
Ages 12+
Baylor College of Medicine · Sites in United States
Abbott Medical Devices · Sites in United States, Australia, Austria and 11 more countries
Ages 18+
Children's National Research Institute · Sites in United States
Ages 7–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Ornithine Carbamoyltransferase Deficiency Disease studies recruiting now, 3 (30%) set no upper age limit and 6 (60%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 2
First in 2007; this study’s year is marked. 2 started in 2022.
This study's enrollment of 37 is above the median of 30 across 28 interventional studies indexed under Ornithine Carbamoyltransferase Deficiency Disease.
Median enrollment 15 across the 12 interventional studies, 66 across the 16 observational. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Ultragenyx Pharmaceutical Inc is the lead sponsor of 63 studies on the registry; 8 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.
Ultragenyx Pharmaceutical Inc has 6 studies filed under Ornithine Carbamoyltransferase Deficiency Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05345171Phase 3Ultragenyx Pharmaceutical IncClinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency | 2027-09 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT04612764Baylor College of MedicineLiver Disease in Urea Cycle Disorders | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Ornithine Carbamoyltransferase Deficiency Disease with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to evaluate the efficacy of DTX301 on the improvement of ornithine transcarbamylase (OTC) function by maintaining safe plasma ammonia levels.
This study is a Phase 3, randomized, double-blind, placebo-controlled study of DTX301 in patients with late-onset OTC deficiency 12 years of age and older.
Participants will be randomized 1:1 to DTX301 or placebo and followed closely for 36-64 weeks. Between Week 36 and Week 64, eligible participants will cross over and receive DTX301 if they had previously received placebo, and some who received DTX301 may receive placebo.
The planned study duration is up to 324 weeks. Upon completion of this study or early withdrawal, all participants who received DTX301 are invited to enroll in the Disease Monitoring Program (DMP) for follow-up for up to an additional 5 years.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply, per protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive single peripheral intravenous (IV) infusion of DTX301 in solution. Between Week 36 and Week 64, participants may receive single peripheral IV infusion of placebo.
Genetic: DTX301 · Other: Placebo · Drug: Oral Corticosteroids · Drug: Placebo for oral corticosteroids · Drug: Sodium Acetate
Participants receive single peripheral IV infusion of placebo. Between Week 36 and Week 64, participants receive single peripheral IV infusion of DTX301 in solution.
Genetic: DTX301 · Other: Placebo · Drug: Oral Corticosteroids · Drug: Placebo for oral corticosteroids · Drug: Sodium Acetate
non-replicating, self-complementary recombinant adeno-associated virus serotype 8 (AAV8) vector
Also known as: avalotcagene ontaparvovec
normal saline infusion
Participants who receive DTX301 solution will receive oral corticosteroids.
Also known as: Prednisolone
Participants who receive Placebo will receive placebo corticosteroids to maintain the study blind
A tracer for the Ureagenesis Rate Test (URT)
Plasma Ammonia as Measured by 24-Hour Ammonia (AUC0-24)
Time frame: Week 36
Complete Responder Rate at the Final Study Visit After DTX301 Exposure
Time frame: Up to 64 Weeks Post DTX301 Infusion
Percentage of Complete Responders or Responders After DTX301 Exposure
Time frame: Up to 64 Weeks Post DTX301 Infusion
Annualized Event Rate of Hyperammonemic Crises (HACs) Pre-DTX301 Exposure vs Post-DTX301 Exposure
Time frame: Pre-enrollment, Baseline, Up to 64 Weeks Post DTX301 Infusion
Annualized Event Rate of Interim Clinical Events (ICEs) Pre-DTX301 Exposure vs Post-DTX301 Exposure
Time frame: Pre-enrollment, Baseline, Up to 64 Weeks Post DTX301 Infusion
Change from Baseline in Plasma Ammonia (AUC0-24)
Time frame: Baseline, Up to Week 36
Change in Plasma Ammonia (AUC0-24) After DTX301 Exposure
Time frame: Up to 64 Weeks Post DTX301 Infusion
Percentage of Participants Who Have Achieved Complete Management Response (CMR) or Management Response (MR) After DTX301 Exposure
Time frame: Up to 64 Weeks Post DTX301 Infusion
Change in Baseline Disease Management (Dietary Protein and Total Scavenger Medication Use) With Plasma Ammonia (AUC0-24)
Time frame: Up to 64 Weeks Post DTX301 Infusion
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs, Related Serious TEAEs and Adverse Events of Special Interest (AESIs)
Time frame: Up to Week 324
Number of Participants With Anti-OTC Antibodies
Time frame: Up to Week 324
Long-Term Durability of Response
Based Upon Number of Complete Responders or Responders That Have ≥ 2 Consecutive Visits as a Complete Responder or Responder and Do Not Return to a Lower Responder Status for \> 1 Consecutive Visit
Time frame: Up to 64 Weeks Post DTX301 Infusion
Change in Plasma Ammonia (AUC0-24) for Participants Who Have an Elevated Ammonia AUC0-24 at Baseline
Time frame: Baseline, Up to 64 Weeks Post DTX301 Infusion
Plan to share: No
Started Oct 2022 (actual). Primary completion is estimated for Sep 2027, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Acetate
Ornithine Carbamoyltransferase Deficiency Disease →
Ultragenyx Pharmaceutical Inc →